Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO
· Real-Time Price · USD
6.75
0.27 (4.17%)
At close: Jun 06, 2025, 3:59 PM
6.83
1.26%
After-hours: Jun 06, 2025, 05:53 PM EDT
4.17% (1D)
| Bid | 6.69 |
| Market Cap | 345.05M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -44.19M |
| EPS (ttm) | -0.63 |
| PE Ratio (ttm) | -10.71 |
| Forward PE | 26.88 |
| Analyst | Buy |
| Ask | 6.85 |
| Volume | 898,713 |
| Avg. Volume (20D) | 1,641,803 |
| Open | 6.50 |
| Previous Close | 6.48 |
| Day's Range | 6.50 - 6.83 |
| 52-Week Range | 3.93 - 7.32 |
| Beta | 1.54 |
About ABEO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ABEO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ABEO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+23.77%
Abeona Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
1 month ago
-0.93%
ABEO stock has given up its prior gain. Abeona Therapeutics shares were trading higher after the company announced FDA approval of ZEVASKYN for treating wounds in patients with recessive dystrophic epidermolysis bullosa.
2 months ago · seekingalpha.com
Abeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call TranscriptAbeona Therapeutics Inc. (NASDAQ:ABEO ) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ET Company Participants Greg Gin – Vice President-Investor Relations and Communications Vish Seshadri – ...